

Consolidated Financial Results for Fiscal 2016

(Reference Data of Financial Statements Fiscal 2016 1st Quarter)

August 3, 2016

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

1. Summary of Consolidated Financial Statements for Fiscal 2016 1st Quarter

(Figures less than one million yen have been omitted)

	FY2015 1st Q	FY2015	FY2016 1st Q	Y o Y increase (decrease)		Plan FY2016	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	27,633	109,730	26,228	(1,405)	94.9%	106,100	(3,630)	96.7%
Operating income	9,234	35,146	8,097	(1,136)	87.7%	28,900	(6,246)	82.2%
Ratio of net sales	33.4%	32.0%	30.9%			27.2%		
Ordinary income	9,362	35,365	8,217	(1,145)	87.8%	29,100	(6,265)	82.3%
Ratio of net sales	33.9%	32.2%	31.3%			27.4%		
Net income	6,300	21,143	5,796	(503)	92.0%	20,800	(343)	98.4%
Ratio of net sales	22.8%	19.3%	22.1%			19.6%		
Comprehensive income	6,460	18,444	5,158	(1,301)	79.8%			
R&D expenses	1,408	5,883	1,899	490	134.8%	10,200	4,317	173.4%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2015 1st Q	FY2015	FY2016 1st Q	%	Plan FY2016	%
Anti-osteoarthritis Artz	8,020	30,760	7,754	96.7%	29,300	95.3%
Anti-nail fungus Clenafin	4,499	19,868	5,796	128.8%	23,800	119.8%
Post-operative anti-adhesive Seprafilm	2,714	11,262	2,701	99.5%	11,500	102.1%
Anti-hyperlipidemia Lipidil	1,123	4,526	1,133	100.8%	4,300	95.0%
Wound healing agent Fiblast Spray	924	3,617	941	101.9%	3,700	102.3%
Generic products	3,330	13,292	3,045	91.4%	12,700	95.5%
Sales of Jublia*	1,717	5,722	1,033	60.2%	4,100	71.7%

(*including sales of API and finished product, royalty revenue, milestone revenue and initial payment)